Comparative Pharmacology
Head-to-head clinical analysis: PINDAC versus ZIAC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PINDAC versus ZIAC.
PINDAC vs ZIAC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vasodilator (arteriolar dilator) reducing afterload; also inhibits platelet aggregation through inhibition of phosphodiesterase III.
ZIAC is a combination of bisoprolol, a cardioselective beta1-adrenergic receptor blocker, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing blood volume.
Oral: 2.5-5 mg twice daily; maximum 20 mg daily.
ZIAC (bisoprolol fumarate/hydrochlorothiazide) 2.5 mg/6.25 mg to 10 mg/6.25 mg orally once daily, titrated at 2-week intervals based on blood pressure response. Maximum dose: 20 mg/12.5 mg per day.
None Documented
None Documented
Terminal elimination half-life is 3-4 hours in healthy individuals, prolonged to 7-15 hours in renal impairment and in elderly patients. Clinical context: dosing interval adjustment recommended for CrCl <30 mL/min.
Bisoprolol: 9–12 h (terminal); HCTZ: 6–15 h (terminal); prolonged in renal impairment; steady state by 5 days
Pindac (pindolol) is eliminated predominantly via hepatic metabolism (60-65%) with renal excretion of unchanged drug (35-40%). Less than 1% is excreted in feces via biliary elimination.
Renal: bisoprolol (50% unchanged), HCTZ (≥95% unchanged); biliary/fecal: bisoprolol (≤2%)
Category C
Category C
Beta Blocker
Beta Blocker + Diuretic